Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*
Ángel Crespo López(Hospital Universitario Infanta Cristina), Robert F. Grover(GlaxoSmithKline (Netherlands)), Jan Bakker(Intensive Care Society), Michael Brockway(St. Johns Hospital), Steven H. Grossman(GlaxoSmithKline (Netherlands)), Jill Donaldson(GlaxoSmithKline (Netherlands)), José A. Lorente(Hospital Universitario de Getafe), Jukka Takala(University of Bern), Antonio Anzueto, Sheila M. Willatts(Erasmus Hospital), Carl Arneson(GlaxoSmithKline (Netherlands)), Angela McLuckie(Guy's Hospital), Laurent Holzapfel(Servier (France)), G.Richard Grove(GlaxoSmithKline (Netherlands)), Michael Silverman(Lakeridge Health), Desmond P. Breen(Royal Hallamshire Hospital), Jay S. Steingrub(Tufts University)
Cited by 921
Related Papers
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.6k
Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units
|Critical Care Medicine|1998|3.5k
Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score
|Intensive Care Medicine|2000|740
Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007
|Critical Care Medicine|2011|675
A Prospective, Randomized Study of Goal-Oriented Hemodynamic Therapy in Cardiac Surgical Patients
|Anesthesia & Analgesia|2000|564